FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Bendamustine Hydrochloride (Treanda) Injection
Status: Discontinuation
»Therapeutic Categories: Oncology

Teva Pharmaceuticals (New 09/01/2017)

Company Contact Information:

Presentation Posting Date Related Information
Bendamustine Hydrochloride, Injection, Solution, Concentrate, 180 MG/2 ML and 45 MG/0.5 ML, (NDC 63459-396-02) and (NDC 63459-395-02) 09/01/2017 Note BENDEKA™ (bendamustine HCl) Injection (63459-348-04) is available to replace TREANDA® (bendamustine HCl) Injection. In addition to BENDEKA™, please note that TREANDA® (bendamustine HCl) for Injection, the lyophilized formulation will continue to be available, 63459-390-08 & 63459-391-20

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English